By Adriano Marchese
Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial.
Shares rose 93% ahead of the morning bell to $105.22.
The Redwood City, Calif., commercial-stage pharmaceutical company said Monday that its treatment relacorilant in conjuction with the chemotherapy drug nab-paclitaxel met the primary endpoint of the Rosella trials, showing improved progression-free survival in patients with platinum-resistant ovarian cancer.
The data showed that patients treated with the combination of relacorilant and chemotherapy experienced a 30% reduction in risk of disease progression compared with patients treated with nab-paclitaxel alone.
Patients with advanced ovarian cancer have had few adequate treatment options, said Alexander Olawaiye, principal investigator in the trial and director of gynecological cancer research at Magee-Women's Hospital of the University of Pittsburgh. He said patients with recurrent forms of the disease eventually develop resistance to available therapies.
"The improvement in survival seen in Rosella, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer," Chief Development Officer Bill Guyer said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 31, 2025 08:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。